Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 60
Filter
1.
Eur J Cancer ; 50(17): 2958-65, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25281526

ABSTRACT

BACKGROUND: pN1c is a novel N-category introduced for colorectal cancer (CRC) in current TNM (Tumour, Node, Metastasis) classification. It represents cancers displaying tumour deposits (TDs) in the fat but no involvement of lymph nodes. pN1c is integrated into the UICC (International Union Against Cancer) staging system and shifts previous stage II cancers (6th edition) to stage III. We investigated the frequency of upstaging and TD prognostic significance. METHODS: 414 CRCs, consecutively collected during a population-based epidemiological study, TNM classified and UICC staged according to the 6th TNM edition were reinvestigated for TD presence. The association with survival was investigated after a median follow-up time of 5years in multivariate analyses among nodal negative and positive cases. RESULTS: TDs were found in 103 (24.9%) cancers and were strongly associated with T-, N- and M-stages (p<0.0001, each). Upstaging of previous stage II cancers by the presence of TDs (pN1c) was found in six of 140 cases (4.3% of stage II, 1.4% of all tumours). For stage III CRC, strongly reduced overall, CRC-specific and recurrence-free survival were observed with the presence of TDs (hazard ratios (HR) 2.29, 95% confidence interval 1.27-4.10, HR 2.51, 1.27-4.98, and HR 2.43, 1.32-4.48, respectively). CONCLUSIONS: Upstaging of CRCs through the introduction of pN1c occurs in less than 5% of previous stage II and less than 2% of all cancers. Given the biologic relevance of TDs, integration into the UICC staging relevant N-category is justified. The high prognostic impact of TDs, however, is not reflected in nodal positive cancers in both the TNM and UICC staging systems.


Subject(s)
Colorectal Neoplasms/pathology , Neoplasm Staging , Adult , Aged , Colorectal Neoplasms/mortality , Colorectal Neoplasms/therapy , Disease-Free Survival , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Prognosis , Survival Analysis
3.
Pathologe ; 32(1): 76-82, 2011 Feb.
Article in German | MEDLINE | ID: mdl-20924763

ABSTRACT

Until recently, two major types of colorectal epithelial polyps were distinguished: the adenoma and the hyperplastic polyp. While adenomas - because of their cytological atypia - were recognized as precursor lesions for colorectal carcinoma, hyperplastic polyps were perceived as harmless lesions without any potential for malignant progression, mainly because hyperplastic polyps lack cytological atypia. Meanwhile, it is evident that the lesions formerly classified as hyperplastic represent a heterogeneous group of polyps, some of which exhibit a significant risk of neoplastic progression. These lesions show characteristic epigenetic alterations not commonly seen in colorectal adenomas and progress to colorectal carcinoma via the so-called serrated pathway (CIMP pathway). This group of polyps is comprised not only of hyperplastic polyps, but also of sessile serrated adenomas (SSA), traditional serrated adenomas (TSA) and mixed polyps, showing serrated and "classical" adenomatous features. In a consensus conference of the working group of gastroenterological pathology of the German Society of Pathology, standardization of nomenclature and diagnostic criteria as well as recommendations for clinical management of these serrated polyps were formulated and are presented herein.


Subject(s)
Adenoma/pathology , Colonic Polyps/pathology , Colorectal Neoplasms/pathology , Precancerous Conditions/pathology , Adenoma/diagnosis , Adenoma/genetics , Adenoma/therapy , Apoptosis/genetics , Biopsy , Cell Division/genetics , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Colonic Polyps/diagnosis , Colonic Polyps/genetics , Colonic Polyps/therapy , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/genetics , Colorectal Neoplasms/therapy , CpG Islands/genetics , DNA Methylation/genetics , Diagnosis, Differential , Epigenesis, Genetic/genetics , Genetic Markers/genetics , Humans , Hyperplasia , Intestinal Mucosa/pathology , Precancerous Conditions/diagnosis , Precancerous Conditions/genetics , Precancerous Conditions/therapy , Prognosis , Terminology as Topic
4.
Dis Esophagus ; 24(2): 63-8, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20626446

ABSTRACT

The frequency and clinical significance of heterotopic gastric mucosa in the upper esophagus is not sufficiently known. Heartburn or dysphagia could result from mucin and/or acid production in this area. We undertook a prospective study in 300 patients with special attention of the endoscopist to this area. Moreover, clinical symptoms were determined by questionnaire before performing endoscopy. A total of 33/300 (11%) of patients had at least one histologically proven gastric inlet patch without gender or age preference. In 20/33 (61%) cases, the heterotopic gastric mucosa was classified as mixed type, in 8/33 (24%) as oxyntic, and in 5/33 (15%) as mucoid. Helicobacter pylori was present in none of the cases. There was no significant association to the presence of a hiatal hernia, reflux esophagitis, Barrett's esophagus, or gastric/duodenal ulcer. Moreover, there was no association to the reported grade of heartburn in the upper or lower part of the esophagus, recurrent hoarseness, or dysphagia. When thoroughly performed, heterotopic gastric mucosa is a quite frequent finding in endoscopy of the upper gastrointestinal tract. The presence of this gastric mucosa in the upper third of the esophagus seems to be rarely the cause of clinical symptoms and little prone to complications.


Subject(s)
Choristoma/pathology , Esophageal Diseases/pathology , Gastric Mucosa/pathology , Endoscopy, Gastrointestinal , Female , Humans , Male
5.
Gut ; 58(4): 483-91, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19039087

ABSTRACT

AIMS: Both epithelial barrier dysfunction and apoptosis resistance of immune cells contribute to the pathogenesis of Crohn's disease. The soluble decoy receptor 3 (DcR3) acts in an anti-apoptotic manner by neutralising the death ligand CD95L. Here, we investigated the possible involvement of DcR3 in Crohn's disease. METHODS: The epithelial fraction of human small intestinal mucosa samples was obtained by laser microdissection. Expression of DcR3 was examined by global gene expression profiling, quantitative reverse transcription polymerase chain reaction, immunoblot analysis, and immunohistochemistry. DcR3 concentrations in the serum of patients with Crohn's disease were measured by enzyme-linked immunosorbent assay. Apoptosis assays were performed to study the effects of DcR3 in intestinal epithelial cells and lamina propria T cells. RESULTS: DcR3 is over-expressed in the epithelial layer of ileum specimens in patients with Crohn's disease, both at actively inflamed and non-active sites. DcR3 serum levels are significantly elevated in patients with active and non-active Crohn's disease as compared to healthy controls. The expression of DcR3 in intestinal epithelial cells is induced by tumour necrosis factor alpha. Increased DcR3 expression is associated with activation of nuclear factor kappa B (NF-kappaB) and results in protection of intestinal epithelial cells and lamina propria T cells from CD95L-induced apoptosis. CONCLUSIONS: DcR3 may promote inflammation in Crohn's disease by inhibiting CD95L-induced apoptosis of epithelial and immune cells as well as by inducing NF-kappaB activation.


Subject(s)
Crohn Disease/physiopathology , Receptors, Tumor Necrosis Factor, Member 6b/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Apoptosis/drug effects , Cell Death/drug effects , Cell Death/physiology , Cell Line , Colon/drug effects , Colon/metabolism , Crohn Disease/metabolism , Crohn Disease/pathology , Fas Ligand Protein/antagonists & inhibitors , Fas Ligand Protein/pharmacology , Female , Humans , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Intestine, Small/metabolism , Male , Microdissection , Middle Aged , NF-kappa B/metabolism , RNA, Messenger/genetics , Receptors, Tumor Necrosis Factor, Member 6b/genetics , Receptors, Tumor Necrosis Factor, Member 6b/metabolism , Receptors, Tumor Necrosis Factor, Member 6b/pharmacology , T-Lymphocytes/drug effects , Tumor Necrosis Factor-alpha/pharmacology , Up-Regulation/drug effects , Young Adult
8.
Oncogene ; 27(46): 6068-74, 2008 Oct 09.
Article in English | MEDLINE | ID: mdl-18574467

ABSTRACT

The mRNA of the ubiquitin-like modifier FAT10 has been reported to be overexpressed in 90% of hepatocellular carcinoma (HCC) and in over 80% of colon, ovary and uterus carcinomas. Elevated FAT10 expression in malignancies was attributed to transcriptional upregulation upon the loss of p53. Moreover, FAT10 induced chromosome instability in long-term in vitro culture, which led to the hypothesis that FAT10 might be involved in carcinogenesis. In this study we show that interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha synergistically upregulated FAT10 expression in liver and colon cancer cells 10- to 100-fold. Real-time RT-PCR revealed that FAT10 mRNA was significantly overexpressed in 37 of 51 (72%) of human HCC samples and in 8 of 15 (53%) of human colon carcinomas. The FAT10 cDNA sequences in HCC samples were not mutated and intact FAT10 protein was detectable. FAT10 expression in both cancer tissues correlated with expression of the IFN-gamma- and TNF-alpha-dependent proteasome subunit LMP2 strongly suggesting that proinflammatory cytokines caused the joint overexpression of FAT10 and LMP2. NIH3T3 transformation assays revealed that FAT10 had no transforming capability. Taken together, FAT10 qualifies as a marker for an interferon response in HCC and colon carcinoma but is not significantly overexpressed in cancers lacking a proinflammatory environment.


Subject(s)
Carcinoma, Hepatocellular/genetics , Carcinoma/genetics , Colonic Neoplasms/genetics , Cytokines/pharmacology , Inflammation Mediators/pharmacology , Liver Neoplasms/genetics , Ubiquitins/genetics , Up-Regulation/drug effects , Animals , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Cells, Cultured , Gene Expression Regulation, Neoplastic/drug effects , HeLa Cells , Humans , Mice , Mice, Inbred C57BL , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Tissue Distribution/drug effects , Ubiquitins/metabolism
9.
Clin Exp Immunol ; 151(3): 496-504, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18234058

ABSTRACT

Human intestinal lamina propria T lymphocytes (LPT), when investigated ex vivo, exhibit functional properties profoundly different from those of peripheral blood T lymphocytes (PBT). One prominent feature represents their enhanced sensitivity to CD2 stimulation when compared to PBT. Given that LPT are hyporesponsive to T cell receptor (TCR)/CD3 stimulation, an alternative activation mode, as mimicked by CD2 triggering in vitro, may be functional in mucosal inflammation in vivo. This study provides insight into signalling events associated with the high CD2 responsiveness of LPT. When compared to PBT, LPT show an increased activation of the phosphoinositide 3/protein kinase B/glycogen synthase kinase 3beta (PI3-kinase/AKT/GSK-3beta) pathway in response to CD2 stimulation. Evidence is provided that up-regulation of this pathway contributes to the enhanced CD2-induced cytokine production in LPT. Given the importance of TCR-independent stimulation for the initiation of intestinal immune responses analysis of signalling pathways induced by 'co-stimulatory' receptors may provide valuable information for therapeutic drug design.


Subject(s)
Intestinal Mucosa/immunology , Phosphatidylinositol 3-Kinases/biosynthesis , T-Lymphocytes/immunology , Up-Regulation/immunology , CD2 Antigens/immunology , CD40 Ligand/metabolism , Cells, Cultured , Cytokines/metabolism , Glycogen Synthase Kinase 3/metabolism , Glycogen Synthase Kinase 3 beta , Humans , Immunity, Mucosal , Interleukin-2/biosynthesis , Leukocyte Common Antigens/analysis , Mucous Membrane/immunology , Phosphatidylinositol 3-Kinases/genetics , Phosphorylation , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/immunology
10.
Eur J Pediatr Surg ; 18(1): 7-12, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18302062

ABSTRACT

INTRODUCTION: 3D imaging and surgical planning for the treatment of embryonal tumors using different techniques (CT versus MRI) are presently under discussion. Up to now, the main focus has been on visualizing the anatomy. Contrast medium dynamics have not been taken into consideration. The aim of the present study was to establish the technical means of integrating the 3D images from functional MRI data into the anatomical images and to determine clinical applications for this approach. MATERIAL AND METHODS: In 11 patients (mean age: 2.4 years) with solid tumors, 26 diagnostic MRI examinations were performed for primary diagnosis, treatment monitoring, or as part of the surgical planning. Seven children presented with neuroblastomas, three with Wilms' tumor, and one with advanced bilateral nephroblastomatosis. The MRI data were acquired using a 1.5-T system. For post-processing, we used volume rendering software, including an evaluation of perfusion. By using color-coded parametric images and integrating functional information, perfusion could be visualized and used for interactive surgical planning. Macroscopic and microscopic sections served as the gold standard for assessing tissue viability. RESULTS: We were able to integrate the dynamic data into the anatomical images for all patients. A good agreement was found between the results of surgical planning, including perfusion mapping, with the surgical site, subsequently produced macroscopic sections and the results of random microscopic examinations. CONCLUSIONS: Perfusion mapping using color-coded parametric images of pediatric abdominal tumors extends the diagnostic techniques currently available. We provide first proof of the possibility of integrating functional information into 3D MR images in children. Monitoring the treatment of nephroblastoma and surgical planning for pediatric embryonal tumors represent potential applications of this technique.


Subject(s)
Abdominal Neoplasms/diagnosis , Abdominal Neoplasms/surgery , Image Processing, Computer-Assisted , Imaging, Three-Dimensional , Neoplasms, Germ Cell and Embryonal/diagnosis , Neoplasms, Germ Cell and Embryonal/surgery , Surgery, Computer-Assisted/methods , Abdominal Neoplasms/blood supply , Child, Preschool , Humans , Infant , Magnetic Resonance Imaging , Neoplasms, Germ Cell and Embryonal/blood supply , Reproducibility of Results
11.
Eur J Clin Invest ; 38(2): 134-42, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18226047

ABSTRACT

BACKGROUND: Cholangiocellular carcinomas and gallbladder carcinomas are highly aggressive tumours with a poor prognosis and are generally regarded as chemoresistant tumours. Overexpression of ATP-binding cassette transporters of the multidrug resistance protein (MDR) and multidrug resistance-related protein (MRP) family in cancer cells is a major cause for the multidrug resistance phenotype in vitro and in vivo. To further define the role of MRP family members in biliary tract cancer, we studied the expression and localization of MRP2 and MRP3 in cholangiocellular carcinomas and gallbladder carcinomas. MATERIALS AND METHODS: The expression and cellular localization of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas and gallbladder carcinomas were analysed by immunohistochemistry using isoform-specific antibodies. Expression of MRP isoforms was studied in vitro in Mz-ChA-1 cells derived from gallbladder adenocarcinoma by reverse transcription-polymerase chain reaction (RT-PCR), immunoblotting and immunofluorescence microscopy. RESULTS: Mz-ChA-1 cells constitutively expressed MDR P-glycoproteins, MRP1, MRP2 and MRP3 by RT-PCR, immunoblotting and immunofluorescence microscopy. MRP2 and MRP3 are expressed in the respective apical and basolateral membrane domains. MRP3 was the predominant MRP isoform in gallbladder carcinomas (93%) and cholangiocellular carcinomas (57%), whereas MRP2 expression was detected in only 29% of gallbladder carcinomas and was undetectable in cholangiocellular carcinomas. CONCLUSIONS: Our findings suggest that the intrinsic multidrug resistance of cholangiocellular and gallbladder carcinomas seems to be independent of MRP2 expression while the expression of MRP3 may contribute to the MDR phenotype.


Subject(s)
Cholangiocarcinoma/metabolism , Drug Resistance, Multiple/genetics , Drug Resistance, Neoplasm/genetics , Gallbladder Neoplasms/metabolism , Membrane Transport Proteins/analysis , Multidrug Resistance-Associated Proteins/analysis , Adult , Aged , Aged, 80 and over , Cholangiocarcinoma/genetics , Gallbladder Neoplasms/genetics , Gene Expression , Humans , Immunoblotting , Membrane Transport Proteins/genetics , Microscopy, Fluorescence , Middle Aged , Multidrug Resistance-Associated Protein 2 , Multidrug Resistance-Associated Proteins/genetics , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured
12.
Br J Cancer ; 97(9): 1271-6, 2007 Nov 05.
Article in English | MEDLINE | ID: mdl-17968430

ABSTRACT

The antiapoptotic Livin/ML-IAP gene has recently gained much attention as a potential new target for cancer therapy. Reports indicating that livin is expressed almost exclusively in tumours, but not in the corresponding normal tissue, suggested that the targeted inhibition of livin may present a novel tumour-specific therapeutic strategy. Here, we compared the expression of livin in renal cell carcinoma and in non-tumorous adult kidney tissue by quantitative real-time reverse transcription-PCR, immunoblotting, and immunohistochemistry. We found that livin expression was significantly increased in tumours (P=0.0077), but was also clearly detectable in non-tumorous adult kidney. Transcripts encoding Livin isoforms alpha and beta were found in both renal cell carcinoma and normal tissue, without obvious qualitative differences. Livin protein in renal cell carcinoma samples exhibited cytoplasmic and/or nuclear staining. In non-tumorous kidney tissue, Livin protein expression was only detectable in specific cell types and restricted to the cytoplasm. Thus, whereas the relative overexpression of livin in renal cell carcinoma indicates that it may still represent a therapeutic target to increase the apoptotic sensitivity of kidney cancer cells, this strategy is likely to be not tumour-specific.


Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Apoptosis , Biomarkers, Tumor/genetics , Carcinoma, Renal Cell/genetics , Gene Expression Regulation, Neoplastic , Inhibitor of Apoptosis Proteins/genetics , Kidney Neoplasms/genetics , Kidney/metabolism , Neoplasm Proteins/genetics , Adaptor Proteins, Signal Transducing/metabolism , Biomarkers, Tumor/metabolism , Carcinoma, Renal Cell/metabolism , Humans , Immunoenzyme Techniques , Inhibitor of Apoptosis Proteins/metabolism , Kidney Neoplasms/metabolism , Neoplasm Proteins/metabolism , RNA, Neoplasm/genetics , RNA, Neoplasm/metabolism , Reverse Transcriptase Polymerase Chain Reaction
13.
Pathologe ; 27(3): 217-21, 2006 May.
Article in German | MEDLINE | ID: mdl-16642392

ABSTRACT

The case of a renal oncocytoma involvement by metastasis from breast carcinoma in a 83-year-old woman is reported. The literature of tumour-into-tumour metastasis is reviewed. In conclusion, metastasis of breast carcinoma to a benign renal tumour is very rare.


Subject(s)
Adenoma, Oxyphilic/secondary , Breast Neoplasms/pathology , Kidney Neoplasms/secondary , Neoplasm Metastasis , Adenoma, Oxyphilic/pathology , Aged, 80 and over , Diagnosis, Differential , Female , Humans , Kidney Neoplasms/pathology
14.
Int J Colorectal Dis ; 21(2): 130-4, 2006 Mar.
Article in English | MEDLINE | ID: mdl-15809837

ABSTRACT

BACKGROUND AND AIMS: Coeliac disease and other disorders of the small intestine are associated with disturbances in mucosal architecture. The most severe injury to tissue architecture is villus atrophy. In coeliac disease, molecules reflecting the state of the villus architecture are not well characterized at present. MATERIALS AND METHODS: Expression of acyl-CoA-synthetase 5 (ACS5) was studied in unaffected human small/large intestinal tissue and in coeliac disease using several methods including molecular techniques, as well as an in situ approach using a novel established monoclonal antibody directed against human ACS5. RESULTS: Strong expression, synthesis, and enzymatic activity of ACS5 were found in normal small intestinal mucosa compared with unaffected colon mucosa. In normal small intestine, ACS5 preferentially located to the epithelium covering villi. In coeliac disease, expression of ACS5 was regularly associated with differentiation of villi. Thus, ACS5 was found in the villus epithelium of the small intestine with coeliac disease of Marsh grades I, II, IIIa, or IIIb respectively. In Marsh grade IIIc coeliac disease lesions, strong expression of ACS5 was detectable neither in the surface epithelium nor in the epithelium lining hyperplastic crypts. CONCLUSION: These data suggest that ACS5 is a very suitable marker molecule for the detection of villus atrophy in the small intestine.


Subject(s)
Celiac Disease/enzymology , Coenzyme A Ligases/genetics , Gene Expression , Intestine, Small/enzymology , RNA/genetics , Adolescent , Adult , Aged , Biopsy , Blotting, Western , Celiac Disease/genetics , Celiac Disease/pathology , Child , Child, Preschool , Coenzyme A Ligases/biosynthesis , Humans , Immunohistochemistry , Intestine, Small/pathology , Middle Aged , Reverse Transcriptase Polymerase Chain Reaction
15.
Gut ; 54(7): 944-9, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15951539

ABSTRACT

BACKGROUND AND AIMS: Conflicting results exist about the presence of Mycobacterium avium subspecies paratuberculosis (MAP) specific IS900 DNA in Crohn's disease (CD) tissues. Therefore, we examined IS900 in a large number of gut samples from patients with CD (n = 100) and ulcerative colitis (UC, n = 100), and in non-inflamed control tissues (nIBD, n = 100). We hypothesised that IS900 DNA detection might be associated with distinct clinical phenotypic characteristics in CD. METHODS: The prevalence of MAP DNA in surgically resected tissues was examined using a mechanical-enzymatic disruption technique and nested IS900 specific polymerase chain reaction (PCR). CD patients were stratified according to the criteria of the Vienna classification and other clinical characteristics. RESULTS: IS900 PCR detection rate was significantly higher in CD tissue samples (52%) than in UC (2%) or nIBD (5%) specimens (p<0.0001). In CD patients, IS900 DNA was detected in samples from both diseased small bowel (47%) as well as from the colon (61%). No firm association between MAP specific IS900 detection rates and clinical phenotypic characteristics in CD could be established. However, corticosteroid medication constituted a factor which tended to have a negative influence on IS900 DNA detection rates in CD (p<0.01). CONCLUSIONS: The presence of MAP specific IS900 DNA is a predominant feature of CD. Therapeutic intervention against MAP might represent a potential target for disease mitigation in Crohn's disease.


Subject(s)
Crohn Disease/microbiology , Paratuberculosis/complications , Adult , Aged , Colitis, Ulcerative/microbiology , DNA, Bacterial/analysis , Female , Humans , Intestines/microbiology , Male , Middle Aged , Mycobacterium avium subsp. paratuberculosis/isolation & purification , Polymerase Chain Reaction/methods
16.
Gut ; 54(7): 966-71, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15951544

ABSTRACT

BACKGROUND AND AIMS: We examined the hypothesis of an anti-inflammatory effect of phosphatidylcholine in ulcerative colitis. METHODS: A phase IIA, double blind, randomised, placebo controlled study was performed in 60 patients with chronic active, non steroid dependent, ulcerative colitis, with a clinical activity index (CAI) of > or = 4. Retarded release phosphatidylcholine rich phospholipids and placebo were administered at a dose of 6 g daily over three months. The primary end point was a change in CAI towards clinical remission (CAI < or = 3) or CAI improvement by > or = 50%. Secondary end points included > or = 50% changes in endoscopic activity index (EAI), histology, and quality of life scores. RESULTS: Induction of clinical remission (CAI < or = 3) as the primary outcome variable was attained by 16 (53%) patients in the phosphatidylcholine treated group compared with three (10%) in the placebo group (p<0.00001). The rate of clinical remission and CAI improvement was 90% in the phosphatidylcholine group and only 10% in the placebo group. A median drop of seven points in the CAI score (70% improvement) was recorded in the phosphatidylcholine group compared with no change in the placebo group. Secondary end point analysis revealed concomitant drops in EAI and histology scores (p = 0.00016 and p = 0.0067 compared with placebo, respectively). Improvement in quality of life was reported by 16 of 29 evaluated patients in the phosphatidylcholine group compared with two of 30 in the placebo group (p = 0.00005). CONCLUSION: Retarded release oral phosphatidylcholine is effective in alleviating inflammatory activity caused by ulcerative colitis.


Subject(s)
Colitis, Ulcerative/drug therapy , Phosphatidylcholines/therapeutic use , Administration, Oral , Adult , Chronic Disease , Colitis, Ulcerative/pathology , Colonoscopy , Delayed-Action Preparations , Double-Blind Method , Female , Humans , Male , Middle Aged , Phosphatidylcholines/administration & dosage , Prospective Studies , Quality of Life , Severity of Illness Index , Treatment Outcome
17.
Rofo ; 177(7): 986-91, 2005 Jul.
Article in German | MEDLINE | ID: mdl-15973601

ABSTRACT

PURPOSE: Experimental feasibility study of a new MR-Coil concept for enhanced visualization of the gastric wall. MATERIAL AND METHODS: The newly developed single-loop receiver coil for endoluminal imaging (Fraunhofer Institute, St. Ingbert, Germany) was evaluated in 4 explanted pig stomachs in a 1.5T MR unit (Siemens Symphony, Erlangen, Germany) with T1 w and T2 w MR sequences in three planes. The new coil consists of a foldable and self-expanding single loop coil (receiver coil) of a shape memory metal (nitinol). It was covered with a biocompatible material (silicone) to prevent direct contact of the wire with stomach tissue. The coil assumes a circular configuration with a diameter of 8 cm because of its memory metal properties. The flexible characteristics of the material used allow the passage through the instrument channel (13 mm diameter) of a specially designed MR-compatible endoscope. The purpose of our study was to assess feasibility of the coil design as a first step in developing a new endoluminal MRI-concept. Additionally the number and signal intensity of visible gastric wall layers were evaluated and findings were correlated with histopathological results of a pig stomach. RESULTS: The new coil concept was a feasible system in all 4 cases and showed good image quality for analysis. On T1 w images, 3 layers were visible in all cases, and on T2 w images 4 different gastric wall layers were seen in 2 cases. Due to histopathological correlation, the different gastric wall layers were identified as follows: mucosa, submucosa and muscularis propria if three layers were depicted; in cases of 4 visible wall layers, serosa and subserosa could be detected additionally. For each gastric wall layer, a distinct signal intensity was found. CONCLUSION: The new MR coil concept for endoluminal imaging proved to be a feasible technique. Good differentiation of gastric wall layers in the pig stomach could be demonstrated. We have shown that endoscopic MR-imaging with our new coil concept is a valuable technique for the visualization of gastric wall layers. Due to this fact, follow-up studies including assessing safety aspects are necessary to finally conduct an experimental-clinical study on in-vivo human gastric specimens to detect tumor growth and morphology within the gastric wall. Endoscopic MRI may have the potential in the future to overcome today's limitations of diagnostic imaging in gastric cancer.


Subject(s)
Endoscopy, Gastrointestinal/methods , Equipment Failure Analysis , Gastroscopes , Magnetic Resonance Imaging/instrumentation , Stomach/cytology , Animals , Equipment Design , Feasibility Studies , Magnetic Resonance Imaging/methods , Reproducibility of Results , Sensitivity and Specificity , Swine
18.
Histopathology ; 46(5): 490-7, 2005 May.
Article in English | MEDLINE | ID: mdl-15842630

ABSTRACT

AIMS: Rheumatoid arthritis (RA) and pigmented villonodular synovitis (PVNS) are aggressive diseases with progressive joint destruction. The present study aims to define cell cycle phases, polyploidy and the immunophenotype of proliferating synovial cells in both diseases. METHODS AND RESULTS: Synovial tissues from patients with proliferative-active RA, localized and diffuse PVNS were analysed by DNA flow cytometry, immunohistochemistry and double immunofluorescence with confocal laser scan microscopy. Expression of macrophage markers (CD68/CD163), fibroblast markers (h4Ph/CD55) and Ki67 antigen was examined. Synovial cells positive for either macrophage or fibroblast markers as well as double-labelled cells were found in both RA and PVNS. In RA, CD68/CD163+ synoviocytes were preferentially located in the vicinity of the synovial lining layer, while they were more randomly distributed in PVNS. Of cases with diffuse PVNS, 20% showed an aneuploid cell pattern. All samples of localized PVNS and RA were diploid. Proliferative activity was significantly higher in aneuploid PVNS. CONCLUSIONS: In spite of their histologically homogeneous appearance, proliferating synovial cells display a heterogeneous immunophenotype in both RA and PVNS, indicating functional properties of both macrophages and fibroblasts. Aneuploidy seems to be a special feature of diffuse PVNS.


Subject(s)
Arthritis, Rheumatoid/physiopathology , Synovitis, Pigmented Villonodular/pathology , Antigens, CD/analysis , Antigens, Differentiation, Myelomonocytic/analysis , Arthritis, Rheumatoid/genetics , Arthritis, Rheumatoid/metabolism , Biomarkers/analysis , CD55 Antigens/analysis , Cell Proliferation , DNA/genetics , DNA/metabolism , Fibroblasts/chemistry , Fibroblasts/pathology , Flow Cytometry , Humans , Immunohistochemistry/methods , Ki-67 Antigen/analysis , Macrophages/chemistry , Macrophages/pathology , Procollagen-Proline Dioxygenase/analysis , Receptors, Cell Surface/analysis , Synovial Membrane/chemistry , Synovial Membrane/pathology , Synovitis, Pigmented Villonodular/genetics , Synovitis, Pigmented Villonodular/metabolism
19.
Histol Histopathol ; 20(2): 409-14, 2005 04.
Article in English | MEDLINE | ID: mdl-15736044

ABSTRACT

Metaplastic and heterotopic epithelia are frequently found in the human intestine. The recently cloned human acyl-CoA synthetase 5 (ACS5) is a key enzyme in providing cytosolic acyl-CoA thioesters. The aim of the study was to identify and to locate the expression of ACS5 in the gastric body and the small intestine with metaplasia or heterotopia by different methods. In the normal gastrointestinal tract, ACS5 was predominantly found in the villus epithelium of the small intestine, but not in the gastric mucosa. Of note, strong expression of ACS5 was also detectable in intestinal metaplasia of the stomach. Inversely, ACS5 expression could neither be detected in heterotopic gastric mucosa of the corpus type nor in gastric, pseudopyloric, or antral metaplasia of the small intestine. In conclusion, our data implicate that ACS5 is a suitable differentiating marker molecule in the gastrointestinal tract.


Subject(s)
Coenzyme A Ligases/genetics , Coenzyme A Ligases/metabolism , Gastrointestinal Tract/enzymology , Gastrointestinal Tract/pathology , Adult , Aged , Base Sequence , Case-Control Studies , Choristoma/enzymology , Choristoma/genetics , Choristoma/pathology , Epithelium/enzymology , Epithelium/pathology , Gastric Mucosa/enzymology , Gastric Mucosa/pathology , Gastrointestinal Diseases/enzymology , Gastrointestinal Diseases/genetics , Gastrointestinal Diseases/pathology , Gene Expression , Humans , Intestinal Mucosa/enzymology , Intestinal Mucosa/pathology , Metaplasia , Middle Aged , RNA, Messenger/genetics , RNA, Messenger/metabolism
20.
Gut ; 54(2): 207-14, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15647183

ABSTRACT

BACKGROUND AND AIMS: Erroneous thymic selection of developing T lymphocytes may be responsible for the expansion of self reactive T cells or may contribute to the absence of regulatory T cells important in controlling peripheral inflammatory processes. Colitis in bone marrow (BM) transplanted Tgepsilon26 mice is induced by abnormally activated T cells developing in an aberrant thymic microenvironment. We investigated the protective role of regulatory CD4+CD25+ T cells in this model. METHODS: BM from (C57BL/6 x CBA/J) F1 mice was transplanted into specific pathogen free Tgepsilon26 mice (BM-->Tgepsilon26). Transplanted mice received no cells (control), sorted CD4+CD25+, or CD4+CD25- cells from mesenteric lymph nodes (MLN) of normal mice. MLN cell subsets were analysed using membrane markers. Cytokine secretion of MLN cells was measured using intracellular cytokine staining and cytokine secretion in anti-CD3 stimulated cell cultures. Colitis was measured by histological scores. RESULTS: CD4+CD25+ cells were reduced in the MLNs of BM-->Tgepsilon26 mice. Transfer of regulatory CD4CD4+CD25+ but not of CD4+CD25- cells reduced the number of MLN CD4+ T cells in BM-->Tgepsilon26 recipients and increased the number of MLN CD8+ cells, thereby normalising the CD4+/CD8+ ratio. CD4+CD25+ but not CD4+CD25- cell transfer into BM-->Tgepsilon26 mice reduced the number of tumour necrosis factor alpha+ CD4+ cells and increased the secretion of transforming growth factor beta by MLN cells. Transfer of 3 x 10(5) CD4+CD25+ cells after BM transplantation into Tgepsilon26 mice prevented colitis whereas CD4+CD25- cells had no protective effect. CONCLUSIONS: These results suggest that defective selection or induction of regulatory T cells in the abnormal thymus is responsible for the development of colitis in BM-->Tgepsilon26 mice. Transfer of CD4+CD25+ cells can control intestinal inflammation in BM-->Tgepsilon26 mice by normalising the number and function of the MLN T cell pool.


Subject(s)
Bone Marrow Transplantation/immunology , CD4-Positive T-Lymphocytes/immunology , Colitis/prevention & control , Lymphocyte Transfusion , T-Lymphocyte Subsets/immunology , Animals , Bone Marrow Transplantation/adverse effects , CD8-Positive T-Lymphocytes/immunology , Colitis/immunology , Colitis/pathology , Lymph Nodes/immunology , Lymphocyte Activation/immunology , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Receptors, Interleukin-2/analysis , Tumor Necrosis Factor-alpha/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...